Will Alten Be A Significant Clinical Trials CRO?

/ August 31, 2021

ER&D services largest pure-play, Alten, has ambitions as a clinical trials contract research organization (CRO). During Q2 2021, the company completed the acquisition of Cmed. Cmed, a clinical trial CRO based in the UK. It is a small firm with EUR 20m in revenues and 180 consultants. It has specialized in oncology, immuno-oncology, cell therapy, and rare disease.

Alten: A Big Rebound in Q2

/ August 18, 2021

Alten impressed investors with its Q2 rebound: revenues had a big rebound (+19.7% yoy at cc/cs) to EUR 714m. We had anticipated this solid rebound: the comps were very favorable (Q2 2020 was down 18.4% yoy organically).

Alten Makes its Largest Acquisition Ever, in Digital

/ November 15, 2020

Alten is to make its largest acquisition, with Milan-headquartered SDG Group. SDG has revenues of EUR 76m and a headcount of 950. Its operating margin is ~10%. We estimate the price paid by Alten to ~EUR 60m.

Sweco, Nordics’ Alten, Impressed in Q3!

/ November 7, 2020

The more we get to know Sweco, the more we think it is similar to Alten. Sweco impressed in Q3 2020 by limiting its revenue decline by 2% yoy at cc/cs, to SEK 4,547m (~USD 526m).

Europe Has Entered its Second Lockdown. A Look at Financial Implications

/ November 1, 2020

Europe has now entered its second lockdown. The lockdowns have different restrictions levels and different lengths. The UK and France are running for the full month of November. Officials in the two countries have, however, warned the lockdown might last longer, until Christmas at least.

Earnings Preview: Revenues of Alten to Plunge in Q2

/ July 15, 2020

ER&D’s largest pure-play globally, Alten, will be announcing its Q2 2020 revenue by the end of July. The company had a very decent Q1, with a 4% CC/CS revenue growth. However, it warned that revenues would be down by ~22% in Q2.

Alten Slows Down in Q4. Points to Market Adjustment

/ February 3, 2020

Alten’s revenues in Q4 slowed down to a growth of +7.3% yoy (at CC/CS ), following double-digit CC/CS growth during Q1-Q3 2019. The company suffered from a demanding comparison basis (+13.7% in Q4 2018), and one lesser working day in several countries (a 0.15% impact on the group’s revenues).

2018: A Year in Review

/ January 3, 2019

2018 was an eventful year: the top ER&D vendors accelerated their M&A activities. Alten continued to deploy its business model. HCL Tech’s ERS unit had a superb year